Ash Stevens, Inc. (ASI) has received FDA approval of its facility in Riverview, MI to manufacture the API in ARIAD Pharmaceuticals’ drug Iclusig (ponatinib), which was recently approved to treat chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant to prior TKI therapy.   “We are very proud to be ARIAD Pharmaceuticals&#...